Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies

Wong ZC. et al, (2024), CANCER RESEARCH, 84

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187

KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Karali CS. et al, (2024), BLOOD, 144, 2527 - 2528

Modelling niche influences on blood cancer development

Psaila B., (2024), HEMATOLOGIE, 30, 121 - 122

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806

RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Brierley CK. et al, (2024), BLOOD, 144, 3146 - 3147

Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms- All Clones Are Not Equal

Chowdhury O. et al, (2024), BLOOD, 144, 3615 - 3616

Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia

Louka E. et al, (2024), BLOOD, 144, 822 - 823

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk

Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner

Luis TC. et al, (2023), Nature Communications, 14

Changing treatment changing prognosis of mutations

Vyas P., (2023), Blood, 142, 1583 - 1585

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), Br J Haematol

Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts.

Moura PL. et al, (2023), Cancer research

A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), STAR Protoc, 4

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

O'Sullivan JM. et al, (2023), Leukemia

Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity

Go S. et al, (2023)

Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner.

Luis TC. et al, (2023), Nat Commun, 14

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.

Henriksen PA. et al, (2023), Circulation

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Jakobsen NA. et al, (2023)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Daver NG. et al, (2023), J Clin Oncol

«
...
2
3
4
5
6
7
8
...
»